skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea

Original Research

(2411) Views  (718) Full article downloads

Authors: Abdulmoghni Al-Barrag, Mutahar Al-Shaer, Nabil Al-Matary, et al

Published Date July 2010 Volume 2010:4 Pages 801 - 808
DOI: http://dx.doi.org/10.2147/OPTH.S9709

Abdulmoghni Al-Barrag1, Mutahar Al-Shaer1, Nabil Al-Matary2, Mohammed Al-Hamdani2

1Ophthalmic Department, Faculty of Medicine and Health Sciences, Sana’a University, Sana’a, Republic of Yemen; 2Ophthalmic Department, Military Hospital, Sana’a, Republic of Yemen

Objective: To evaluate the efficacy and risks of complications of pulse dosing of topical 5-fluorouracil (5-FU) in the treatment of corneal intraepithelial neoplasia (CIN), and conjunctival squamous cell carcinoma (SCC).

Design: Prospective, noncomparative case series.

Participants: Fifteen patients with histological evidence CIN or SCC of the conjunctiva and cornea were identified by tumor biopsy.

Methods: All patients clinically evident of CIN, or SCC were evaluated, with maximum 30 months of follow-up were treated with pulsed dosing of 1% 5-FU. Treatment cycles were defined as four times per day for 4 days using the medication followed by 30 days without medication. The number of initial treatment was six cycles.

Results: The mean age of the 15 patients was 50.8 years (range 25–78 years). Excision biopsy proved seven cases as CIN, and eight cases as locally invasive SCC. All patients remained disease free with a mean follow-up of 14.53 months (range 6-30 months). Additional chemotherapy was given after the initial treatment cycles, only for one case. 5-FU caused mild temporary local irritation, but no long-term intraocular or extra ocular complications.

Conclusions: Adjuvant 1% topical 5-FU appears to be effective in the prevention of recurrence of conjunctival or corneal CIN and SCC after excision biopsy. Our results indicate that at least six cycles of topical 1% 5-FU is required to prevent local recurrence in the long term. It is well-tolerated and an effective method of treatment. No complications that would preclude use of our dose regimen were noted.

Keywords: chemotherapy, fluorouracil, neoplasia, treatment cycles




 

Other articles by Dr A Al-Barrag



Readers of this article also read:

Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Health literacy and health seeking behavior among older men in a middle-income nation
Retinal vein occlusion: pathophysiology and treatment options
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Walking just after a meal seems to be more effective for weight loss than waiting for one hour to walk after a meal
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy